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Introduction
The 25th Annual San Antonio Breast Cancer Symposium
attracted nearly 5000 physicians and researchers in
breast oncology, as well as other health care professionals
and patient advocates with an interest in breast cancer.
This meeting has become a key forum for the presentation
and discussion of both translational scientific aspects as
well as clinical aspects of breast cancer care. The present
report will focus on the clinical highlights of the meeting.
The preclinical and translational research presented at the
meeting is discussed in another report, also published in
the present issue of Breast Cancer Research [1].
This year, the traditional WL McGuire memorial lecture
was given by Michael Baum (University College London,
UK). Baum described his 30 years’ experience in breast
cancer research in an entertaining and wide-ranging talk.
In particular, he outlined what he sees as a paradigm shift
in the design of clinical trials from an empirical approach
to a hypothesis-driven approach. There were two further
clinical plenary lectures, given by Stephen Feig (Mount
Sinai School of Medicine, New York, USA) and Craig
Jordan (University of California, San Francisco, CA, USA).
These critical, informative reviews concerned the validity
and interpretation of existing mammography trials. There
were also minisymposia addressing the changing face of
adjuvant therapy and the use of aromatase inhibitors.
General sessions comprised short communications of
original research, panel discussions of clinical scenarios
and more than 500 poster presentations.
Adjuvant therapy
The current status of adjuvant chemotherapy was sum-
marised in a minisymposium by Hyman Muss (University of
Vermont, Burlington, VT, USA) and Charles Vogel (Univer-
sity of Miami, FL, USA). On the basis of data from the
Oxford Overviews, chemotherapy regimes that incorporate
anthracyclines are still preferred to those that do not. This
was reinforced by an update of the National Cancer Insti-
tute of Canada Clinical Trials Group (NCIC CTG) MA.5
trial given by Kathleen Pritchard (Toronto-Sunnybrook
Cancer Center, Toronto, Canada), which demonstrated
superiority of an anthracycline regime (cyclophosphamide,
epirubicin and 5-fluorouracil) over cyclophosphamide,
methotrexate and 5-fluorouracil (10-year disease free sur-
vival, 52% versus 45%; P=0.005) [2].
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Abstract
The Annual San Antonio Breast Cancer Symposium has become a key forum for the presentation and
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In some groups such as the elderly or high-risk node-
negative patients, however, it may be possible and desir-
able to omit the anthracycline component, and this is
being investigated by the Cancer and Leukaemia Group B
(CALGB 40101 and CALGB 49907). On the basis of
results from the Breast Cancer International Research
Group (BCIRG) 001 and CALGB 9344 trials, many
oncologists in the United States also incorporate a taxane
into adjuvant chemotherapy regimes. Trials are underway
to assess whether paclitaxel or docetaxel (weekly or three-
weekly) is the best agent in the adjuvant setting.
However, a report of the CALGB 9741 trial given by Mark
Citron on behalf of the CALGB highlighted the potential
importance not only of the agents used, but of the dose
density of adjuvant chemotherapy [3]. CALGB 9741 is a
randomised phase III trial of sequential chemotherapy
using doxorubicin, cyclophosphamide and paclitaxel, or
concurrent doxorubicin and cyclophosphamide followed
by paclitaxel at 14-day intervals versus 21-day intervals.
Patients on the 2-week schedules were given prophylactic
filgrastim support. Disease-free survival at 3 years follow-
up was superior for dose-dense versus conventional
scheduling (85% versus 81%, P=0.0072). Overall sur-
vival was also superior (92% versus 90%, P=0.014), but
there was no difference in these outcomes based on the
use of sequential versus concurrent therapy. There were
no neutropaenia-related deaths, and fewer cases of
grade 4 neutropaenia were encountered in the dose-
dense arms of the study. The number of events so far
experienced has been lower than expected from the null
hypothesis, such that the results of this trial must be
regarded as preliminary. Nonetheless, dose density may
prove to be an important determinant of the efficacy of
adjuvant chemotherapy.
At the 24th Annual San Antonio Breast Cancer Sympo-
sium, Baum presented a first analysis of the Arimidex,
Tamoxifen, Alone or in Combination (ATAC) trial. At this
year’s meeting, Aman Buzdar (MD Anderson, Houston,
TX, USA) presented a further analysis (median followup,
47 months) on behalf of the international trialists group
[4]. The trial randomised 9366 postmenopausal women
with breast cancer (who had completed surgery, radio-
therapy and/or chemotherapy) between the adjuvant
endocrine therapy arms. When first published (median fol-
lowup, 33 months), an improved disease-free survival was
reported for anastrozole over tamoxifen (89.4% versus
87.4%, P=0.013), with the combination arm offering no
advantage over tamoxifen alone [5]. Buzdar’s report
focused on the monotherapy arms of the study. The prob-
ability of a first event (local or distant recurrence, new
primary breast cancer or death) was lower at 48 months in
the anastrozole arm compared with the tamoxifen arm
(14% risk reduction, P=0.03). The absolute difference in
first-event rates between the arms has increased from
1.5% at 3 years to 2.4% at 4 years. Benefits were greater
still in the group known to be hormone receptor-positive
(2.9% absolute difference at 48 months).
An additional 7 months of safety data were presented in
poster form by Richard Sainsbury (Royal Free and Univer-
sity College Medical School, London, UK) on behalf of the
ATAC trialists group [6]. These data continue to show
lower rates of endometrial cancer, thromboembolic events
and cerebrovascular events with anastrozole than with
tamoxifen. There were also significantly fewer withdrawals
due to drug-related adverse events in the anastrozole-
treated group (5.1% versus 7.2%, P<0.0001). However,
there were more musculoskeletal events and fractures in
the anastrozole arm (30.3% versus 23.7%, and 7.1%
versus 4.4%, respectively). Buzdar concluded that the
data support the use of adjuvant anastrozole in this patient
population. Several other planned and ongoing trials are
also looking at the role of adjuvant aromatase inhibitors,
given alone or in combination with selective estrogen
receptor modulators, sequentially or concurrently, and for
differing durations.
The increased fracture rate seen in the ATAC trial patients
receiving anastrozole is of concern, and it may be that
some of these patients benefit from the concurrent use of
bisphosphonates. Of relevance to this, data presented by
Michael Gnant (Austrian Breast and Colorectal Study
Group, Vienna, Austria) demonstrate that the bisphospho-
nate zoledronate may be able to counteract bone mineral
density loss in premenopausal women treated with
goserelin and anastrozole [7].
Aromatase inhibitors
Following on from the ATAC data, a minisymposium was
devoted to the topic of aromatase inhibitors, with empha-
sis on response prediction, breast cancer prevention and
clinical application.
Matthew Ellis (Duke University Breast Cancer Program,
Durham, NC, USA) gave an overview of current clinical
practice. While the superiority of aromatase inhibitors over
tamoxifen is generally accepted in cases of advanced
disease, their use in the adjuvant setting is still controver-
sial and it is important to look at all aspects of their use,
including the long-term side effects. The development of
resistance is of particular concern. Research in recent
years has focused on human epidermal receptor-2
(HER-2)-driven activation of the oestrogen receptor as a
major mechanism of resistance to endocrine therapy.
While this is certainly relevant, it is unlikely to represent
the whole story. In vitro data show that letrozole-resitant
cells have a low rate of HER-2 positivity and continue to
proliferate in a manner that suggests independence from
the oestrogen receptor. Similarly, in cases of advanced
disease, primary resistance to letrozole can still develop115
despite the presence of trastuzumab, suggesting that
other growth stimulatory pathways are also important. Ellis
stressed the need for further trials to assess the efficacy
of aromatase inhibitors in the adjuvant and neoadjuvant
setting, to examine potential synergy when combined with
novel signalling agents, and to investigate novel mecha-
nisms of resistance.
Despite a reduction in mortality from breast cancer, the
incidence continues to rise and the need for preventative
measures is clear. Mitch Dowsett (Royal Marsden Hospi-
tal, London, UK) acknowledged the potential role of aro-
matase inhibitors in this setting and outlined a number of
forthcoming trials. However, he stressed the need for a
well-developed strategy both in terms of who to treat and
how to counteract unwanted side effects. Existing trials
suggest that the preventative effects of tamoxifen are pre-
dominantly seen in those who are likely to develop oestro-
gen receptor-positive tumours. Features predicting for the
development of oestrogen receptor-positive tumours
(such as age, atypical hyperplasia, breast and bone
density, and levels of oestradiol, oestrone and testos-
terone) may therefore become important components of
preventative trial targeting.
Targeted therapy was taken further by William Miller (Edin-
burgh Breast Unit, Edinburgh, UK), who discussed the
role of aromatase inhibitors in suppressing oestrogen
locally within the breast tumour tissue, in addition to
reducing circulating serum levels. Peripheral serum
aromatase has been shown to fall by > 90% in women
after 3 months of treatment and this is associated with a
concomitant fall in serum oestradiol, but such a response
cannot be predicted. Serum oestradiol levels in pre-
menopausal women are high. Oestradiol reaches the
breast via diffusion, and levels in the local breast tissue are
predictably lower. However, this situation may be reversed
in postmenopausal women; serum levels of oestradiol fall
as ovarian function ceases but hormone levels within the
breast can remain paradoxically high, suggesting that in
some cases oestradiol may be synthesised de novo within
the breast tissue. Infusional studies in postmenopausal
women using radiolabelled androgen and oestrogen have
provided evidence for oestrogen production, both peri-
pherally and locally within the breast tumours themselves.
There is interpatient variability but, overall, patients with
high levels of in situ oestrogen synthesis respond well to
treatment with aromatase inhibitors. This provides interest-
ing insight into a possible predictor of response to these
compounds, and also raises the possibility of enhancing
treatment response using a method of local drug delivery.
Treatment of advanced breast cancer
The number of drug treatment options in metastatic breast
cancer has increased in recent years, but this remains a
highly challenging area, particularly in patients with rela-
tively chemotherapy-resistant or heavily pretreated
disease. Trastuzumab+paclitaxel has previously been
shown to be superior to paclitaxel alone in HER-2-positive
breast cancer [8].
Nicolas Robert (US Oncology Inc, Houston, TX, USA) pre-
sented encouraging results at this meeting of a collabora-
tive phase III trial comparing the combination of
trastuzumab + paclitaxel with the combination of
trastuzumab + paclitaxel + carboplatin (TPC) in HER-2/
neu-positive patients with advanced disease [9]. The
objective response rate was greater with TPC versus than
with trastuzumab+paclitaxel (52% versus 36%, P=0.04).
There was also a significant improvement in the time to
progression with TPC (11.2 months versus 6.9 months).
Similar findings were seen whether HER-2 status had been
confirmed using immunohistochemical analysis or fluores-
cence  in situ hybridisation. Although there was more
myelosuppression with TPC, this was not accompanied by
more septic or haemorrhagic episodes, and there was also
no significant difference in the neurotoxicity observed.
A number of posters and presentations addressed the
potential clinical efficacy of novel agents, either alone or in
combination with conventional cytotoxics. Bevacizumab is
a humanised monoclonal antibody to vascular endothelial
factor that has shown clinical activity as monotherapy in
patients with metastatic disease. Kathy Miller (Indiana
Cancer Pavilion, Indianapolis, IN, USA) presented data
from a phase III trial of bevacizumab in combination with
capecitabine in patients who had received prior
chemotherapy [10]. The overall response rate was supe-
rior for the combination arm over capecitabine alone (20%
versus 9%), but no improvement in progression-free sur-
vival was observed. Moreover, the toxicity profile was poor
with a significant increase in hypertension and throm-
boembolic events.
Kathy Albain (Loyola University Medical Center, Maywood,
IL, USA) discussed the results of an open-label, phase II,
multicentre trial of ZD 1839 (Iressa) as monotherapy in
advanced disease [11]. Of the patients, 14.3% achieved a
partial response or stable disease for ≥5 months and, sub-
jectively, Iressa appeared to improve symptoms of bone
pain, although this was not a preplanned endpoint. While
limited clinical activity has been reported to date, studies
such as these are important as they demonstrate a proof
of principal and support the design of further clinical trials.
Conclusion
Basic and translational research now exerts a considerable
influence over clinical breast cancer treatment and research.
The Annual San Antonio Breast Cancer Symposium is criti-
cal to the success of this relationship as it enables the dis-
semination of information between all sections of the breast
cancer research and treatment community.
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